From ETF Channel: Exchange traded funds (ETFs) trade just like stocks, but instead of ”shares” investors are actually buying and selling ”units”. These...
With the share price in the doldrums, Alnylam hosted an R&D day that unveiled a significant early-stage/pre-clinical platform and highlighted numerous long-term
CAMBRIDGE, Mass. and CARLSBAD, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Biogen Inc (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Biogen...
For Immediate ReleaseChicago, IL – December 12, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts...
It has been a disappointing year for the biotech industry. The NASDAQ Biotechnology Index (^NBI has lost 5% so far in 2018. While the year started on a choppy note, things were...
Biogen Inc. (NASDAQ:BIIB) announced that it has obtained a worldwide license to develop and commercialize Ionis Pharmaceuticals’ (NASDAQ:IONS) pipeline candidate, BIIB067...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Buy|
|Technical Indicators||Strong Sell||Neutral||Strong Buy||Sell||BUY|
|Summary||Strong Sell||Sell||Strong Sell||Strong Sell||Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Engulfing Bearish||1W||1||Dec 02, 2018|
|Advance Block Bearish||5H||1||Dec 11, 2018 06:00AM|
|Bullish Engulfing||1H||1||Dec 11, 2018 02:00PM|
|Three Outside Up||5H||2||Dec 10, 2018 03:00PM|
|Engulfing Bearish||15||2||Dec 11, 2018 03:15PM|
|Bank of America||24.58||25.40||24.53||-0.18||-0.73%||78.55M||11/12|
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.Read More
|U.S. Commodity Futures Trading Commission (United States)||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$2000||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.